Imagine applying these arguments to a drug trial. The patients in the control group have done better than those given the drug, and there is evidence that the drug might be harmful. But the drug companies like their profits, and want to keep the drug on the market. Though “somewhat at odds” with the evidence, this is a “political reality.” Getting rid of the drug would reopen the debate on the search for a cure. Change is costly – true. But what is the purpose of a review, if the status quo is always to be preferred?
Tuesday, January 03, 2006
Database Directive must die!
Jamie Boyle comments acidly on the recent European Commission review of the Database Directive, which concluded that the Directive was damaging the European database industry but was extremely blasé about the implications of this conclusion: